Myriad Genetics Inc (MYGN)

32.30
0.33 1.03
NASDAQ : Services
Prev Close 31.97
Open 32.06
Day Low/High 31.64 / 32.48
52 Wk Low/High 28.82 / 46.24
Volume 712.22K
Avg Volume 944.10K
Exchange NASDAQ
Shares Outstanding 70.30M
Market Cap 2.25B
EPS 1.10
P/E Ratio 21.60
Div & Yield N.A. (N.A)

Latest News

Myriad MyRisk® Hereditary Cancer Test Demonstrates The Magnitude Of Breast And Ovarian Cancer Risk In Nearly 100,000 Patients

Myriad MyRisk® Hereditary Cancer Test Demonstrates The Magnitude Of Breast And Ovarian Cancer Risk In Nearly 100,000 Patients

New Studies at the 2016 ASCO Annual Meeting Demonstrate a 2- to 40-Fold Increased Risk

Myriad Will Present Three New Hereditary Cancer Studies At The ASCO Annual Meeting

Myriad Will Present Three New Hereditary Cancer Studies At The ASCO Annual Meeting

New Data Highlight the Power of the Myriad myRisk® Hereditary Cancer Test To Identify More Mutation Carriers Without Increased Risk of Distress

Myriad Acquires Sividon Diagnostics

Myriad Acquires Sividon Diagnostics

Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict®

Myriad To Present New Research At The 2016 ASCO Annual Meeting

Myriad To Present New Research At The 2016 ASCO Annual Meeting

Data Demonstrate Expanded Utility of the Myriad myRisk® Hereditary Cancer Test

Myriad To Present Three New Studies At The AUA Annual Meeting

Myriad To Present Three New Studies At The AUA Annual Meeting

New Data Highlight the Power of the Prolaris® Test to Predict 10-Year Oncologic Outcomes in Patients with Low-Risk Localized Prostate Cancer

Trade-Ideas: Myriad Genetics (MYGN) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Myriad Genetics (MYGN) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Myriad Genetics (MYGN) as a strong on high relative volume candidate

Myriad Genetics (MYGN) Weak On High Volume Today

Myriad Genetics (MYGN) Weak On High Volume Today

Trade-Ideas LLC identified Myriad Genetics (MYGN) as a weak on high relative volume candidate

Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks

Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks

Looking at this list, you realize things turned out to be a lot better than many of the bears had feared, Cramer says.

Myriad MyRisk® Hereditary Cancer Article In Journal Of Clinical Oncology Highlights Importance Of Expanding Genetic Testing For Breast Cancer Patients

Myriad MyRisk® Hereditary Cancer Article In Journal Of Clinical Oncology Highlights Importance Of Expanding Genetic Testing For Breast Cancer Patients

Prospective Clinical Study Showed the myRisk Test Identified 70 Percent More Deleterious Mutations than BRCA Testing Alone with 42 Percent of These in Women Over Age 45

Short Interest In Myriad Genetics Moves 11% Lower

Short Interest In Myriad Genetics Moves 11% Lower

The most recent short interest data has been released by the NASDAQ for the 03/15/2016 settlement date, which shows a 2,146,411 share decrease in total short interest for Myriad Genetics, Inc. , to 17,478,486, a decrease of 10.94% since 02/29/2016.

Myriad Genetics Teams Up With Access Health® To Educate The Public About Hereditary Cancer And Genetic Testing

Myriad Genetics Teams Up With Access Health® To Educate The Public About Hereditary Cancer And Genetic Testing

Experts Include Angelina Jolie Breast Surgeon, Dr. Kristi Funk

The Myriad MyRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations In Patients With Endometrial Cancer

The Myriad MyRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations In Patients With Endometrial Cancer

New Data Presented at the Society for Gynecologic Oncology Annual Meeting

Myriad Presents Second Pivotal Validation Study For Its MyPath® Melanoma Test

Myriad Presents Second Pivotal Validation Study For Its MyPath® Melanoma Test

myPath Melanoma Diagnoses Suspicious Lesions with >90 Percent Diagnostic Accuracy

Watch Out: Barbarians At The Gate For Myriad Genetics (MYGN)

Watch Out: Barbarians At The Gate For Myriad Genetics (MYGN)

Trade-Ideas LLC identified Myriad Genetics (MYGN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Myriad Advances Proprietary MyVision® Variant Classification Tools To A Broader Range Of Cancer Risk Genes

Myriad Advances Proprietary MyVision® Variant Classification Tools To A Broader Range Of Cancer Risk Genes

New Data Presented at the 2016 ACMG Annual Clinical Genetics Meeting

Myriad Genetics Expands Strategic Research Collaboration With AbbVie

Myriad Genetics Expands Strategic Research Collaboration With AbbVie

Companion Diagnostic Portfolio to be Evaluated in Lung Cancer Patients Treated With Veliparib

Myriad Expands Diagnostic Research Collaboration With TESARO And Merck

Myriad Expands Diagnostic Research Collaboration With TESARO And Merck

Companion Diagnostic Portfolio to Evaluate Treatment Response in Patients With Triple Negative Breast Cancer or Ovarian Cancer

Today's Dead Cat Bounce Stock Is Myriad Genetics (MYGN)

Today's Dead Cat Bounce Stock Is Myriad Genetics (MYGN)

Trade-Ideas LLC identified Myriad Genetics (MYGN) as a "dead cat bounce" (down big yesterday but up big today) candidate